

## Protocol Version History

**Name of Trial: ANIMATE:** A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy

**Name of Chief Investigator:** Dr Graham Collins

Version Number	Date	Main changes	Amendment Number	REC Approval Date	MHRA Approval Date	HRA Approval Date	Date of distribution to:				
							Sites	BMS	Lab - HMDS	Lab - Oxford	PET Core lab
1.0	04.01.2018	N/A Initial version	N/A	01.03.2018	27.02.2018	13.04.2018	N/A	N/A	N/A	N/A	N/A
1.1	21.02.2018	Clarification of rationale for treatment dose/schedule at request of MHRA	1	10.04.2018	N/A	17.04.2018	N/A	N/A	N/A	N/A	N/A
2.0	10.04.2018	References to UCL Cancer Institute replaced by The Weatherall Institute of Molecular Medicine, Oxford who will now be undertaking analysis on peripheral blood samples.  Minor changes to eligibility criteria and investigations to bring the protocol more into line with current standard practice.  Minor changes to pharmacovigilance reporting requirements.	2	30.04.2018	20.04.2018	08.05.2018	N/A	N/A	N/A	N/A	N/A